Search
Learn about recent research led by MSK physician-scientist Luc Morris, who is trying to better predict who will benefit from immunotherapy.
A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan Kettering Cancer Center in New York and Lund University in Sweden.
Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.
Sacral neuromodulation has already helped patients with benignly caused fecal incontinence – can it do the same for rectal cancer patients following sphincter-preserving surgery?
Immune checkpoint inhibitors and adoptive T cell therapy have shown success in treating several cancers. Now both approaches are in trials for gynecologic cancers, and researchers think even more applications are possible.
In these incredibly challenging times, healthcare workers are our real-life superheroes! Here at Memorial Sloan Kettering, our amazing staff is working around the clock to keep doing what we do best: providing safe and exceptional care to patients with cancer. From doctors and nurses to security, patient transporters, and cleaning staff, our entire team at MSK remains fiercely dedicated to our mission.
“We could not be more proud of this deserving group of the outstanding GSK students who have been recognized with fellowship support this academic year,” says GSK Dean Michael Overholtzer.
Here’s what to know about breast-feeding during chemotherapy and other treatments for cancer.
Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.
Learn about the difference methods of colorectal cancer screening, including the at-home Cologuard test, from an expert at Memorial Sloan Kettering Cancer Center.